PainReform Ltd. (NASDAQ:PRFX) Sees Large Growth in Short Interest

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 194,929 shares, an increase of 92.4% from the January 15th total of 101,333 shares. Currently, 73.8% of the company’s stock are short sold. Based on an average daily volume of 6,625,219 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 6,625,219 shares, the days-to-cover ratio is presently 0.0 days. Currently, 73.8% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

PainReform Stock Performance

NASDAQ PRFX opened at $2.91 on Friday. PainReform has a one year low of $2.57 and a one year high of $27.35. The stock has a 50-day moving average of $4.03 and a 200 day moving average of $5.62. The company has a market capitalization of $1.16 million, a price-to-earnings ratio of 0.00 and a beta of 0.61.

PainReform (NASDAQ:PRFX) last released its quarterly earnings data on Wednesday, October 1st. The company reported ($2.72) earnings per share for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.